|Bid||103.01 x 1100|
|Ask||103.92 x 800|
|Day's range||101.48 - 104.06|
|52-week range||95.02 - 217.25|
|Beta (5Y monthly)||1.62|
|PE ratio (TTM)||34.44|
|Earnings date||01 Nov 2023 - 06 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||171.28|
These companies are helping change medicine; they could make boatloads of money along the way.
Moderna (NASDAQ: MRNA) used to be a stock market star, climbing 1,700% from the start of 2020 through July of 2021. Investors liked that, and it clearly showed in the stock performance. After all, the vaccine is Moderna's only product right now, and demand for it has declined.
Once a relatively unknown biotech company, Moderna (NASDAQ: MRNA) became a household name when it became one of the first companies to offer a vaccine for the COVID-19 virus. At its peak, Moderna saw quarterly revenue of $7 billion as it sold vaccines to the world. Its stock price followed suit, reaching an all-time high of $484 in mid-2021.